Fundraising FoxKurma Partners — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy.
AI & Machine LearningBiotechDeep TechParis, FR
Jonathan Naccache(Co-founder (Directeur de la publication))in
Co-investorsKima VenturesBreega
Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients.
BiotechDigital HealthMental Health
Delphine Charvin(Founding Chief Executive Officer & Board Director)inMélanie Rouillier(VP, Chief Operations Officer & Co-Founder)inJocelyne Caboche(President of the Scientific Advisory Board & Co-Founder)in
Co-investorsAngelini VenturesCARMA FUNDSambrinvest
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD).
BiotechDigital HealthLongevity
Robert Kirmeier(Founder)inWenzel von der Heydte(CEO & Co-founder)inThomas Kirmeier(COO & Co-founder)
Co-investorsAdBio partnersKhanuBoehringer Ingelheim Venture Fund
Hopia is an AI platform that automates staff scheduling for doctors and caregivers across all hospital departments, using a proprietary symbolic AI to model legal, collective, and individual rules.
AI & Machine LearningDigital HealthSaaS
Matthias Lesage(Founder)inVictoire Bach(Founder)in
Co-investorsIris Capital50 Partners
Laigo Bio develops targeted protein degradation therapies using its SureTACs (Surface Removal Targeting Chimeras) platform, which uses bispecific antibodies to direct cell-surface proteins toward lysosomal degradation via membrane-bound E3 ligases.
BiotechHealthtech
Co-investorsAngelini VenturesCurie Capital
Poppins is a clinically validated digital medical device for children aged 7-11 with dyslexia and reading difficulties.
AI & Machine LearningDigital HealthEdTechHealthtechParis, FR
Co-investorsTechstarsVerve VenturesBNP Paribas DéveloppementBpifranceEurazeo
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.